ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

DTIC-DOME
Leukemias, lymphomas, and other hematologic cancers
Melanoma and other skin cancers
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

DTIC-DOME Rx

Generic Name and Formulations:
Dacarbazine 200mg/vial; pwd for IV infusion after reconstitution and dilution; contains mannitol.

Company:
Bayer Healthcare Pharmaceuticals Inc.

Therapeutic Use:

Indications for DTIC-DOME:

Metastatic malignant melanoma. Second-line therapy for Hodgkin's disease, in combination with other agents.

Adult:

Give by IV infusion. Malignant melanoma: 2–4.5mg/kg/day for 10 days, may repeat every 4 weeks; or 250mg/m2 daily for 5 days, may repeat every 3 weeks. Hodgkin's disease (in combination with other drugs): 150mg/m2 daily for 5 days, may repeat every 4 weeks; or 375mg/m2 on day 1, then repeat every 15 days.

Children:

Not recommended.

Warnings/Precautions:

Monitor CBCs, platelets; may need to discontinue or suspend therapy if hemopoietic toxicity occurs. Pregnancy (Cat.C). Nursing mothers: not recommended.

Pharmacological Class:

Alkylating agent.

Adverse Reactions:

Myelosuppression (eg, leukopenia, thrombocytopenia, anemia), anorexia, nausea, vomiting, flu-like syndrome, alopecia, facial flushing/paresthesia, inj site reactions, anaphylaxis; rare: hepatic necrosis, photosensitivity reactions.

How Supplied:

Vials (20mL)—12

Indications for DTIC-DOME:

Metastatic malignant melanoma. Second-line therapy for Hodgkin's disease, in combination with other agents.

Adult:

Give by IV infusion. Malignant melanoma: 2–4.5mg/kg/day for 10 days, may repeat every 4 weeks; or 250mg/m2 daily for 5 days, may repeat every 3 weeks. Hodgkin's disease (in combination with other drugs): 150mg/m2 daily for 5 days, may repeat every 4 weeks; or 375mg/m2 on day 1, then repeat every 15 days.

Children:

Not recommended.

Warnings/Precautions:

Monitor CBCs, platelets; may need to discontinue or suspend therapy if hemopoietic toxicity occurs. Pregnancy (Cat.C). Nursing mothers: not recommended.

Pharmacological Class:

Alkylating agent.

Adverse Reactions:

Myelosuppression (eg, leukopenia, thrombocytopenia, anemia), anorexia, nausea, vomiting, flu-like syndrome, alopecia, facial flushing/paresthesia, inj site reactions, anaphylaxis; rare: hepatic necrosis, photosensitivity reactions.

How Supplied:

Vials (20mL)—12

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs